Kędzierski Stolarczyk Partnerzy Spółka z Ograniczoną Odpowiedzialnością (KRS 0000974170, NIP 7011091079) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. KĘDZIERSKI STOLARCZYK PARTNERZY operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since June 1, 2022. KĘDZIERSKI STOLARCZYK PARTNERZY's operations are currently suspended.
The company is currently suspended
Suspended since April 30, 2025
Negative equity
Negative equity in 1 of 1 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Kędzierski Stolarczyk Partnerzy
Identity
- Name
- Kędzierski Stolarczyk Partnerzy Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 1, 2022
- Registry status as of
- December 4, 2025
- Latest entry
- December 3, 2025
- Founding act
- 7.03.2024 R., REPERTORIUM A NR 3320/2024, NOTARIUSZ W WARSZAWIE JAKUB KULCZYCKI, KANCELARIA NOTARIALNA SŁAWOMIR BORZĘCKI…
Articles of association history (2)
- March 25, 2025: 25.03.2025, KANCELARIA NOTARIALNA PAWEŁ MATUSIAK, A NR 432/2022
- July 3, 2024: 7.03.2024 R., REPERTORIUM A NR 3320/2024, NOTARIUSZ W WARSZAWIE JAKUB KULCZYCKI, KANCELARIA NOTARIALNA SŁAWOMIR BORZĘCKI JAKUB KULCZYCKI SPÓŁKA CYWILNA, UL. SIENNA NR 86, LOK. 132, 00-815 WARSZAWA, UCHYLENIE DOTYCHCZASOWEJ TREŚCI UMOWY SPÓŁKI I UCHWALENIE NOWEJ TREŚCI UMOWY SPÓŁKI
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
Other activities
Address and contact
- Address
- KRAKOWSKIE PRZEDMIEŚCIE, 16/18, 29A, 00-325, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- CHOJANADRIAN@VP.PL
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Kędzierski Stolarczyk Partnerzy
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli, częste zmiany nazwy spółki. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
2
2/4 yrs
Board changes
1
1/4 yrs
PKD changes
1
1/4 yrs
Name changes
1
1/4 yrs
Data from 4 years of registry activity.
Operational status - Kędzierski Stolarczyk Partnerzy
Founded
June 1, 2022
4 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
1 year
2023 · profitable: 0/1
Registry entries
15
latest: December 3, 2025
Risk signals
Revenue
N/A
2023
Net profit
-7.4 K PLN
2023
Assets
2.2 K PLN
2023
Equity
-4.8 K PLN
2023
Valuation
0 PLN
suspended
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Kędzierski Stolarczyk Partnerzy.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
